About olipudase alfa
Recombinant human acid sphingomyelinase enzyme
Used for
- Long-term enzyme replacement therapy for non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD), also called Niemann-Pick disease types A/B or B.
Usual adult dose
Start at 0.1 mg/kg intravenously; increase gradually to 3 mg/kg every two weeks as tolerated.
Usual dose in children
For children aged 1 year and older: start at 0.03 mg/kg intravenously; increase gradually to 3 mg/kg every two weeks as tolerated.
Common side effects
- Headache
- Fever
- Nausea
- Infusion-related reactions, including rash or breathing difficulties
Important warnings
- Infusion reactions can be severe, including anaphylaxis; treatment requires monitoring.
- Dose increases are gradual to reduce infusion reactions and raised liver enzymes.
- Liver enzyme increases may occur, especially during dose escalation.
- It does not treat neurological disease caused by ASMD.
Pregnancy
Human pregnancy data are limited; use only when the potential benefit justifies possible risk.
Breastfeeding
It is unknown whether olipudase alfa enters breast milk; consider benefits and potential risks.
Interactions
- No clinically significant drug interactions have been established.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.